TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07893535: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BON-106 Alone or in Combination With Other Anticancer Agents in Patients With Advanced

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 96 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07893535 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07893535 Rescue Dossier →